Curium Pharma is a private company, founded in 2000. Its most recent disclosed valuation is $7B. No public ticker exists for the company.
1 valuation. The latest, $7B post-money, was set by the Growth Equity in Nov 2025.
TPGCCVC Capital PartnersGGoldman Sachs Alternatives
LunatePPantheonAArdianCurium develops, manufactures and distributes radiopharmaceutical products used in nuclear medicine, including generators, cold kits and hot products for diagnosing and treating diseases of the thyroid, lungs, liver, bones, brain, heart, glands, kidneys and joints. Its radioactive tracers support early diagnosis and treatment of cancer as well as heart, brain and bone conditions.
Curium runs manufacturing and sales sites across more than 60 countries from headquarters split between Paris and Boston, serving over 6,000 global customers with more than 50 products.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Curium Pharma.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. Curium Pharma availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — Curium Pharma included.
The last valuation is $7B.
Lead investors for each round are in the funding timeline.
The routes section explains what is realistically available for a company at this stage.
No. Curium Pharma is a private company; its shares do not trade on a public exchange.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
